Loading
Loading
Your feedback directly shapes Sporos.
Sign in to track your feedback history
This request for information seeks input from the public on whether any additions or modifications are needed to the safe harbor regulations under the Federal anti-kickback statute or the exceptions to the civil monetary penalty provision prohibiting inducements to beneficiaries (the "Beneficiary Inducements CMP") for emerging direct-to-consumer ("DTC") sales programs established by pharmaceutical manufacturers, including those that will be available through TrumpRx.
Published
Jan 29, 2026
Comments Close
Mar 30, 2026(19d)
Citation
91 FR 3857
Agencies
2
Full text not available in our database.
View on Federal Register →Get a plain-English explanation of what this regulation does, which agencies are responsible, and how it affects existing rules.
No document text available yet
0936-AA15
42 CFR 1001
42 CFR 1003